IL6 and myeloid sarcoma: Moreover, persistent high levels of IL-6 also promoted fat breakdown, release of free fatty acids, and synthesis of very low-density lipoprotein (VLDL) in the liver, further exacerbating dyslipidemia and systemic metabolic disorders, thereby significantly increasing the risk of MS (32, 33).